🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/08/2015 | 140,03 | 141,49 | 138,38 | 139,76 | +0,11% | 2,22% | 949.900 |
| 17/08/2015 | 136,39 | 140,06 | 135,01 | 139,61 | +1,99% | 3,70% | 816.300 |
| 14/08/2015 | 137,25 | 137,62 | 133,96 | 136,88 | -0,36% | 2,67% | 956.600 |
| 13/08/2015 | 137,89 | 140,00 | 136,89 | 137,37 | -0,20% | 2,26% | 1.268.700 |
| 12/08/2015 | 134,48 | 138,29 | 132,13 | 137,64 | +1,30% | 4,58% | 1.160.000 |
| 11/08/2015 | 138,85 | 139,13 | 134,03 | 135,87 | -2,69% | 3,67% | 1.475.700 |
| 10/08/2015 | 139,17 | 143,45 | 139,16 | 139,63 | +1,37% | 3,08% | 1.679.200 |
| 07/08/2015 | 138,94 | 139,50 | 136,03 | 137,74 | -1,22% | 2,50% | 2.440.800 |
| 06/08/2015 | 141,25 | 142,36 | 137,22 | 139,44 | -1,26% | 3,64% | 1.570.300 |
| 05/08/2015 | 141,59 | 143,16 | 139,76 | 141,22 | +0,66% | 2,40% | 1.374.000 |
| 04/08/2015 | 137,81 | 141,84 | 137,13 | 140,30 | +2,42% | 3,42% | 2.013.800 |
| 03/08/2015 | 134,88 | 139,15 | 134,68 | 136,99 | +1,47% | 3,31% | 2.161.100 |
| 31/07/2015 | 134,89 | 136,00 | 133,02 | 135,00 | -0,34% | 2,21% | 1.545.500 |
| 30/07/2015 | 126,09 | 135,90 | 121,15 | 135,46 | +7,83% | 11,70% | 3.099.800 |
| 29/07/2015 | 128,28 | 128,98 | 125,27 | 125,62 | -2,09% | 2,89% | 1.785.300 |
| 28/07/2015 | 124,47 | 128,56 | 122,41 | 128,30 | +4,11% | 4,94% | 1.944.900 |
| 27/07/2015 | 124,24 | 125,35 | 121,31 | 123,23 | -1,81% | 3,25% | 2.042.300 |
| 24/07/2015 | 130,02 | 130,70 | 124,62 | 125,50 | -4,09% | 4,68% | 1.362.800 |
| 23/07/2015 | 131,71 | 131,95 | 129,93 | 130,85 | -0,13% | 1,53% | 869.900 |
| 22/07/2015 | 130,51 | 132,12 | 129,94 | 131,02 | +0,04% | 1,67% | 978.500 |
| 21/07/2015 | 133,66 | 133,89 | 129,91 | 130,97 | -1,87% | 2,98% | 1.046.800 |
| 20/07/2015 | 134,68 | 135,15 | 132,95 | 133,47 | -0,52% | 1,63% | 1.045.600 |
| 17/07/2015 | 134,29 | 134,48 | 132,28 | 134,17 | +0,20% | 1,64% | 1.276.700 |
| 16/07/2015 | 133,49 | 134,32 | 133,12 | 133,90 | +0,28% | 0,90% | 2.004.200 |
| 15/07/2015 | 130,54 | 136,36 | 130,25 | 133,53 | +3,16% | 4,68% | 3.082.400 |
| 14/07/2015 | 124,99 | 129,83 | 123,24 | 129,44 | +4,19% | 5,27% | 1.784.700 |
| 13/07/2015 | 123,81 | 124,56 | 123,00 | 124,24 | +1,05% | 1,26% | 1.067.000 |
| 10/07/2015 | 122,75 | 123,39 | 121,20 | 122,95 | +1,70% | 1,78% | 1.520.500 |
| 09/07/2015 | 123,01 | 123,90 | 120,88 | 120,89 | -0,53% | 2,46% | 1.660.300 |
| 08/07/2015 | 126,64 | 126,86 | 120,94 | 121,54 | -4,66% | 4,67% | 1.994.100 |